RARE DISEASE
Hyper-IgE syndrome
Hyper-IgE syndrome
Hyper-IgE syndrome
Drug discovery
1
drug
With orphan designation
Overview
Hyper-IgE syndrome (HIES) is a rare primary immunodeficiency characterized by recurrent skin and lung infections, eczema, and elevated serum IgE levels (>2000 IU/mL). Most cases arise from STAT3 (autosomal dominant) or DOCK8 (autosomal recessive) mutations, impairing Th17 differentiation and immune regulation. Clinical features include cold abscesses, pneumatoceles, skeletal/dental anomalies, and increased malignancy risk. Chronic infections drive morbidity, necessitating lifelong multidisciplinary management [1][6][11][17].
Burden
High morbidity from recurrent infections (20% develop pneumatoceles) and secondary lung damage [1][6][19].
Malignancy risk: 6.5% lifetime prevalence (lymphomas, SCC) [4][11][17].
Reduced quality of life due to chronic symptoms, frequent hospitalizations, and complications like fractures/scoliosis [9][16][17].
Therapies
Prophylaxis: Daily antistaphylococcal antibiotics (e.g., TMP-SMX), antifungals, and antivirals [1][11][16].
Biologics: Omalizumab (anti-IgE) for asthma/allergic components; dupilumab (IL-4/13 inhibitor) for refractory eczema [3][8][11].
Curative: Hematopoietic stem cell transplant for DOCK8 deficiency [1][14].
Categories: rare genetic diseases, rare immunological diseases
Research Papers
381 drug discovery papers about Hyper-IgE syndrome, with 2 first-in-class and 3 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
381 drug discovery papers about Hyper-IgE syndrome, with 2 first-in-class and 3 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-08-13 | Hyper-IgE syndromes in pediatrics: clinical spectrum, differential diagnosis, and management
Abstract Hyper-IgE syndromes (HIES) are rare inborn errors of immunity (≈1 per million) caused by pathogenic variants in STAT3, DOCK8 or IL6ST. They present with very high serum immunoglobulin E (IgE), recurrent bacterial or fungal infections, eczema and characteristic organ involvement. The autosomal dominant STAT3-deficient form features early-onset eczema, “cold” abscesses, recurrent pneumonias with pneumatoceles and skeletal or dental anomalies. Autosomal recessive forms such as DOCK8 or PGM3 deficiency show a more severe phenotype with viral skin infections, allergy, asthma and increased malignancy risk. HIES should be suspected in children with IgE >2000 IU/mL plus recurrent sinopulmonary or skin infections, severe eczema, atypical viral infections or a National Institutes of Health Hyper-IgE Syndrome (NIH HIES) score >40. Differentiation from severe atopic dermatitis, asthma, eosinophilic disorders and parasitic infections is essential. Evaluation includes eosinophils, lymphocyte subsets, T-helper 17 (Th17) cell analysis and targeted genetic testing. Management involves antimicrobial prophylaxis, treatment of complications, dermatologic care and genotype-based hematopoietic stem cell transplantation (HSCT), which is curative in DOCK8 but less effective in STAT3 deficiency. Early genomic confirmation enables timely recognition, identification of red flags, and genotype-specific therapy to improve long-term outcomes.
2026-07-20 | The V3 Phase Architecture Applied to the Entire Human Humoral Immune System: A Complete, Certifiable Ada/SPARK Framework Simulating the Assembly of All Four Immunoglobulin Isotypes (IgM, IgG, IgA, IgE) with Pathological Stress Testing Across 10 Immunological Diseases — Validated by Inverse Invariant Collapse and GNATprove 100%
s ABSTRACT: Background & Biological Hypothesis: Classical immunology often views humoral immunodeficiencies, autoimmune disorders, and hypersensitivity reactions as isolated biochemical anomalies governed by complex molecular cascades. This study provides formal proof for a novel biophysical paradigm: human humoral immunity functions as a unified phase-equilibrium system governed by deterministic biophysical invariants (V3 energy invariant Ψ_V3 = 48,016.8 kg/m² and critical bioelectric potential Φ_critical = -51.1 mV). Within this framework, biological health is defined as structural phase stability, whereas immune pathologies represent predictable, threshold-driven phase ruptures. Biological Proof & Mechanistic Discovery: Through high-integrity computational modeling of all four major immunoglobulin classes (IgM, IgG, IgA, IgE), we demonstrate that specific immunopathologies do not occur randomly, but are triggered precisely when individual biophysical parameters cross non-negotiable physical thresholds: • IgM & Assembly Topology: Pentameric IgM integrity requires strict k = 7 heptadic closure via the J-chain. We prove that a drop below k = 5 prevents ring closure, dumping truncated monomers into the bloodstream and causing Waldenström macroglobulinemia. Furthermore, an bioelectric potential shift above Φ > -40.0 mV disrupts polypeptide folding energy, triggering Selective IgM Deficiency, while loss of vesicular transport coherence (< 50%) leads to Hyper-IgM Syndrome. • IgG & Structural Flexibility: Proper H2L2 domain folding coherence is required for secretable IgG; falling below 60% coherence triggers endo-reticular degradation, causing Hypogammaglobulinemia. Hinge region destabilization below 70% impairs receptor binding dynamics, causing Myasthenia Gravis, while endosomal pH-FcRn gradient disruption halts maternal-fetal transfer, driving Hemolytic Disease of the Fetus and Newborn (HDFN). • IgA & Mucosal Shielding: Mucosal protection strictly depends on the presence of the Secretory Component (SC); its absence completely strips mucosal immunity, resulting in Selective IgA Deficiency. Additionally, hinge O-glycosylation below an 80% threshold alters protein solubility, proving that IgA Nephropathy (Berger’s Disease) is driven by threshold-dependent glomerular self-aggregation. • IgE & Allergic Signaling: IgE over-coherence (> 90%) drives unchecked production seen in Hyper-IgE (Job's) Syndrome. Conversely, when allergen-mediated FcεRI crosslinking density exceeds 30%, the mast-cell membrane equilibrium collapses instantly, releasing massive histamine surges in Anaphylactic Shock. Significance for Immunology: This work formally proves that immunological diseases are quantifiable physical phase ruptures. By mapping ten distinct clinical conditions to exact mathematical thresholds, the V3 framework demonstrates that humoral pathologies share a single universal law of phase rupture. This transforms clinical immunology from a descriptive science into a predictive, deterministic biophysical discipline, offering a new foundation for therapeutic target design and precision immunotherapeutics.
2026-07-15 | A Rare Case of Hyper-IgE Syndrome in a Two-Year-Old Child with Recurrent Pneumonia and Generalized Eczematous Dermatitis
Hyper-IgE syndrome (HIES), also known as Job syndrome, is a rare primary immunodeficiency disorder characterized by markedly elevated serum immunoglobulin E (IgE) levels, recurrent sinopulmonary and cutaneous infections, chronic eczematous dermatitis, eosinophilia, and skeletal or connective tissue abnormalities. The autosomal dominant form is most commonly caused by mutations in the STAT3 gene, resulting in impaired T-helper 17 (Th17) cell differentiation and defective neutrophil recruitment. The rarity of the disorder, overlapping clinical manifestations with atopic dermatitis and bronchial asthma, and variable disease severity frequently delay diagnosis, thereby increasing the risk of irreversible pulmonary complications such as bronchiectasis and pneumatoceles. Early recognition and multidisciplinary management are therefore essential to reduce morbidity and improve long-term outcomes.
2026-06-17 | [Guillain-Barré syndrome following allogeneic hematopoietic stem cell transplantation in a pediatric patient: a case report and literature review].
A 10-year-old girl diagnosed with hyper-IgE syndrome for more than six years developed dizziness and symmetrical progressive limb weakness one week prior to hospital admission, occurring 4 months after allogeneic hematopoietic stem cell transplantation. On post-transplant day 121, dizziness and progressive, symmetric limb weakness appeared. Cerebrospinal fluid analysis revealed albuminocytologic dissociation. Electromyography confirmed multiple peripheral nerve lesions, consistent with the diagnosis of Guillain-Barré syndrome. Intravenous immunoglobulin therapy showed limited efficacy, whereas corticosteroid therapy produced significant clinical improvement. Neurological symptoms fully resolved after treatment; however, severe chronic graft-versus-host disease occurred subsequently. Based on this case, related literature was reviewed and summarized to provide references for early diagnosis, mechanistic investigation, and treatment options.
2026-06-02 | [Allogeneic Hematopoietic Stem Cell Transplantation for Children with Hyper-IgE Syndrome].
To summarize the clinical characteristics, treatment outcomes, and prognosis of two children with STAT3 gene mutation-associated hyper-IgE syndrome(HIES) who underwent allogeneic hematopoietic stem cell transplantation(allo-HSCT). A retrospective analysis was performed on two pediatric patients with STAT3-mutated HIES (STAT3-HIES) who received allo-HSCT. Data included baseline clinical features, transplant protocols, post-transplant outcomes, complications (graft-versus-host disease, infection, virus reactivation), serum IgE levels, and long-term follow-up. The two patients (one male, one female; ages 2 years 10 months and 10 years 10 months at transplant) received peripheral blood stem cells from HLA 9/10-matched unrelated donors and were conditioned with the classic BUCY regimen(busulfan+cyclophosphamide+antithymocyte globulin). Neutrophils and platelets engraftment were achieved on day+11 and day +9/+11, respectively. Complete donor chimerism(100%) was confirmed on day+15 post-transplant. No grade II-IV acute GVHD or viral reactivation occurred. Serum IgE levels decreased markedly at 30 days post-transplant compared to pre-transplant. Pulmonary CT findings (e.g., infection foci,cavitation) improved significantly. By the last follow-up (April 30, 2025), both children survived, and their quality of life improved significantly (infection control, resolution of skin eczema, and improvementin organ function). For children with STAT3-mutated HIES who experience recurrent severe respiratory infections impairing quality of life, allo-HSCT with a suitable donor can effectively control infection, improve immune abnormalities, and long-term outcomes.
2026-08-13 | Hyper-IgE syndromes in pediatrics: clinical spectrum, differential diagnosis, and management
Abstract Hyper-IgE syndromes (HIES) are rare inborn errors of immunity (≈1 per million) caused by pathogenic variants in STAT3, DOCK8 or IL6ST. They present with very high serum immunoglobulin E (IgE), recurrent bacterial or fungal infections, eczema and characteristic organ involvement. The autosomal dominant STAT3-deficient form features early-onset eczema, “cold” abscesses, recurrent pneumonias with pneumatoceles and skeletal or dental anomalies. Autosomal recessive forms such as DOCK8 or PGM3 deficiency show a more severe phenotype with viral skin infections, allergy, asthma and increased malignancy risk. HIES should be suspected in children with IgE >2000 IU/mL plus recurrent sinopulmonary or skin infections, severe eczema, atypical viral infections or a National Institutes of Health Hyper-IgE Syndrome (NIH HIES) score >40. Differentiation from severe atopic dermatitis, asthma, eosinophilic disorders and parasitic infections is essential. Evaluation includes eosinophils, lymphocyte subsets, T-helper 17 (Th17) cell analysis and targeted genetic testing. Management involves antimicrobial prophylaxis, treatment of complications, dermatologic care and genotype-based hematopoietic stem cell transplantation (HSCT), which is curative in DOCK8 but less effective in STAT3 deficiency. Early genomic confirmation enables timely recognition, identification of red flags, and genotype-specific therapy to improve long-term outcomes.
2026-07-20 | The V3 Phase Architecture Applied to the Entire Human Humoral Immune System: A Complete, Certifiable Ada/SPARK Framework Simulating the Assembly of All Four Immunoglobulin Isotypes (IgM, IgG, IgA, IgE) with Pathological Stress Testing Across 10 Immunological Diseases — Validated by Inverse Invariant Collapse and GNATprove 100%
s ABSTRACT: Background & Biological Hypothesis: Classical immunology often views humoral immunodeficiencies, autoimmune disorders, and hypersensitivity reactions as isolated biochemical anomalies governed by complex molecular cascades. This study provides formal proof for a novel biophysical paradigm: human humoral immunity functions as a unified phase-equilibrium system governed by deterministic biophysical invariants (V3 energy invariant Ψ_V3 = 48,016.8 kg/m² and critical bioelectric potential Φ_critical = -51.1 mV). Within this framework, biological health is defined as structural phase stability, whereas immune pathologies represent predictable, threshold-driven phase ruptures. Biological Proof & Mechanistic Discovery: Through high-integrity computational modeling of all four major immunoglobulin classes (IgM, IgG, IgA, IgE), we demonstrate that specific immunopathologies do not occur randomly, but are triggered precisely when individual biophysical parameters cross non-negotiable physical thresholds: • IgM & Assembly Topology: Pentameric IgM integrity requires strict k = 7 heptadic closure via the J-chain. We prove that a drop below k = 5 prevents ring closure, dumping truncated monomers into the bloodstream and causing Waldenström macroglobulinemia. Furthermore, an bioelectric potential shift above Φ > -40.0 mV disrupts polypeptide folding energy, triggering Selective IgM Deficiency, while loss of vesicular transport coherence (< 50%) leads to Hyper-IgM Syndrome. • IgG & Structural Flexibility: Proper H2L2 domain folding coherence is required for secretable IgG; falling below 60% coherence triggers endo-reticular degradation, causing Hypogammaglobulinemia. Hinge region destabilization below 70% impairs receptor binding dynamics, causing Myasthenia Gravis, while endosomal pH-FcRn gradient disruption halts maternal-fetal transfer, driving Hemolytic Disease of the Fetus and Newborn (HDFN). • IgA & Mucosal Shielding: Mucosal protection strictly depends on the presence of the Secretory Component (SC); its absence completely strips mucosal immunity, resulting in Selective IgA Deficiency. Additionally, hinge O-glycosylation below an 80% threshold alters protein solubility, proving that IgA Nephropathy (Berger’s Disease) is driven by threshold-dependent glomerular self-aggregation. • IgE & Allergic Signaling: IgE over-coherence (> 90%) drives unchecked production seen in Hyper-IgE (Job's) Syndrome. Conversely, when allergen-mediated FcεRI crosslinking density exceeds 30%, the mast-cell membrane equilibrium collapses instantly, releasing massive histamine surges in Anaphylactic Shock. Significance for Immunology: This work formally proves that immunological diseases are quantifiable physical phase ruptures. By mapping ten distinct clinical conditions to exact mathematical thresholds, the V3 framework demonstrates that humoral pathologies share a single universal law of phase rupture. This transforms clinical immunology from a descriptive science into a predictive, deterministic biophysical discipline, offering a new foundation for therapeutic target design and precision immunotherapeutics.
2026-07-15 | A Rare Case of Hyper-IgE Syndrome in a Two-Year-Old Child with Recurrent Pneumonia and Generalized Eczematous Dermatitis
Hyper-IgE syndrome (HIES), also known as Job syndrome, is a rare primary immunodeficiency disorder characterized by markedly elevated serum immunoglobulin E (IgE) levels, recurrent sinopulmonary and cutaneous infections, chronic eczematous dermatitis, eosinophilia, and skeletal or connective tissue abnormalities. The autosomal dominant form is most commonly caused by mutations in the STAT3 gene, resulting in impaired T-helper 17 (Th17) cell differentiation and defective neutrophil recruitment. The rarity of the disorder, overlapping clinical manifestations with atopic dermatitis and bronchial asthma, and variable disease severity frequently delay diagnosis, thereby increasing the risk of irreversible pulmonary complications such as bronchiectasis and pneumatoceles. Early recognition and multidisciplinary management are therefore essential to reduce morbidity and improve long-term outcomes.
2026-06-17 | [Guillain-Barré syndrome following allogeneic hematopoietic stem cell transplantation in a pediatric patient: a case report and literature review].
A 10-year-old girl diagnosed with hyper-IgE syndrome for more than six years developed dizziness and symmetrical progressive limb weakness one week prior to hospital admission, occurring 4 months after allogeneic hematopoietic stem cell transplantation. On post-transplant day 121, dizziness and progressive, symmetric limb weakness appeared. Cerebrospinal fluid analysis revealed albuminocytologic dissociation. Electromyography confirmed multiple peripheral nerve lesions, consistent with the diagnosis of Guillain-Barré syndrome. Intravenous immunoglobulin therapy showed limited efficacy, whereas corticosteroid therapy produced significant clinical improvement. Neurological symptoms fully resolved after treatment; however, severe chronic graft-versus-host disease occurred subsequently. Based on this case, related literature was reviewed and summarized to provide references for early diagnosis, mechanistic investigation, and treatment options.
2026-06-02 | [Allogeneic Hematopoietic Stem Cell Transplantation for Children with Hyper-IgE Syndrome].
To summarize the clinical characteristics, treatment outcomes, and prognosis of two children with STAT3 gene mutation-associated hyper-IgE syndrome(HIES) who underwent allogeneic hematopoietic stem cell transplantation(allo-HSCT). A retrospective analysis was performed on two pediatric patients with STAT3-mutated HIES (STAT3-HIES) who received allo-HSCT. Data included baseline clinical features, transplant protocols, post-transplant outcomes, complications (graft-versus-host disease, infection, virus reactivation), serum IgE levels, and long-term follow-up. The two patients (one male, one female; ages 2 years 10 months and 10 years 10 months at transplant) received peripheral blood stem cells from HLA 9/10-matched unrelated donors and were conditioned with the classic BUCY regimen(busulfan+cyclophosphamide+antithymocyte globulin). Neutrophils and platelets engraftment were achieved on day+11 and day +9/+11, respectively. Complete donor chimerism(100%) was confirmed on day+15 post-transplant. No grade II-IV acute GVHD or viral reactivation occurred. Serum IgE levels decreased markedly at 30 days post-transplant compared to pre-transplant. Pulmonary CT findings (e.g., infection foci,cavitation) improved significantly. By the last follow-up (April 30, 2025), both children survived, and their quality of life improved significantly (infection control, resolution of skin eczema, and improvementin organ function). For children with STAT3-mutated HIES who experience recurrent severe respiratory infections impairing quality of life, allo-HSCT with a suitable donor can effectively control infection, improve immune abnormalities, and long-term outcomes.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
1 orphan drug designation for Hyper-IgE syndrome.
1 orphan drug designation for Hyper-IgE syndrome.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
Recombinant humanized immunoglobulin gamma 1 monoclonal antibody (mAb) directed against the CemX segment of human membrane-bound immunoglobulin E (mIgE) | antibodies | FDA | 2017-09-28 | — | Oneness Biotech Co., Ltd. |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.